Skip to main content
main-content

Tipp

Weitere Artikel dieser Ausgabe durch Wischen aufrufen

01.11.2012 | main topic | Ausgabe 21-22/2012

Wiener Medizinische Wochenschrift 21-22/2012

Usage and limitations of liquid chromatography-tandem mass spectrometry (LC–MS/MS) in clinical routine laboratories

Zeitschrift:
Wiener Medizinische Wochenschrift > Ausgabe 21-22/2012
Autor:
Christoph Seger

Summary

Technical maturation of liquid chromato-graphy tandem mass spectrometry (LC–MS/MS) brought this technology into most tertiary care clinical laboratories worldwide. It extended the technological armamentarium of clinical laboratories significantly, both in analytical and economical terms. Especially in therapeutic drug monitoring, endocrinology, and toxicology, it became an indispensable routine tool. Although well-designed LC–MS/MS assays generally outperform immunoassays because of increased accuracy, sensitivity, precision, and analytical multiplexing capability, they are not free from analytical problems. Besides limitations in selectivity due to the occurrence of “isobaric” interferences, unpredictable ion yield attenuations, known as “ion suppression effect,” have to be considered. In addition, most LC–MS/MS methods used in clinical laboratories are still laboratory-developed tests (“in-house assays”) operating on very heterogeneous instrument configurations. Consequently, assay heterogeneity and lack of traceability to reference procedures or materials may lead to an increased imprecision in proficiency testing as well as inaccurate result reporting if basic rules of assay validation and “post marketing” surveillance are violated.

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Literatur
Über diesen Artikel

Weitere Artikel der Ausgabe 21-22/2012

Wiener Medizinische Wochenschrift 21-22/2012 Zur Ausgabe

editorial

Biomarkers